Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

NAMSBullishIndustry Newsnews

High materiality7/10

NewAmsterdam Doses First Participant in SPINOZA Alzheimer’s Trial

Sep 29, 2026, 8:18 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Milestone dosing in SPINOZA plus positive biomarker context (BROADWAY) could re-rate the stock if readouts trend favorably; European rights add optional upside, though near-term data is required for durable moves.

AI summary

What happened, with direct paths to the underlying reporting

NewAmsterdam announced the first dosing in SPINOZA, a Phase 2b trial of obicetrapib in preclinical Alzheimer's disease. The trial will measure plasma biomarkers such as p-tau217 and cognitive endpoints over 52 weeks in about 400 ApoE-defined participants. Positive BROADWAY biomarker signals bolster rationale for expanding obicetrapib's AD program, including potential European commercialization with Menarini.

First participant dosed in SPINOZA Phase 2b trial of obicetrapib.
SPINOZA enrolls ~400; 52-week double-blind period; biomarker endpoints include p-tau217.
BROADWAY analysis supports biomarker link; ApoE4 carriers show strongest response.
Europe commercialization rights granted to Menarini; potential near-term revenue.
SPINOZA readouts could influence ongoing REMBRANDT, RUBENS, PREVAIL programs.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.